Drugs / DENVax
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03342898 | Feb → May 2018 | dengue disease | Takeda | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-11-22 | Takeda | Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration takeda.com ↗ |
| 2016-09-07 | Takeda | Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003) takeda.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DENVax | “The vaccine tested in this study is TDV also known as TAK-003 (DENVax).” NCT03342898 ↗ |
| Known as | TAK-003 | “The vaccine tested in this study is TDV also known as TAK-003 (DENVax).” NCT03342898 ↗ |
| Known as | TDV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03342898 ↗ |
| Route | Subcutaneous | “TDV, 0.5 mL, injection, SC” NCT03342898 ↗ |